moatshark My

All holdings

Denali Therapeutics

DNLI

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
0
In their latest 13F (Q3 2026)
See who
Value held
$0k
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Price at Q1 ’26 end
$19.20
+16.3% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+16.3%Q1 ’26
Q1 ’26: +16.3%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
0Q2 ’25
0Q3 ’25
1Q4 ’25
1Q1 ’26
0Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 0; Q3 ’25: 0; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 0; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Denali Therapeutics.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

No manager on this site held it in their latest 13F.

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Denali Therapeutics
Bought or soldFiling
4 Sep 2026Chin Peter ScottChief Medical Officer▼ Sold1,654$22.29$37kForm 4
2 Sep 2026Thornberry NancyDirector▼ Sold10,824$22.85$247kForm 4
2 Sep 2026Thornberry NancyDirector▼ Sold615$23.74$15kForm 4
1 Sep 2026Schuth Alexander O.COFO and Secretary▼ Sold2,768$23.44$65kForm 4
11 Aug 2026Schuth Alexander O.COFO and Secretary▼ Sold2,857$25.07$72kForm 4

About the company

Sector
Health care · Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
160m at 31 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$0k2016
$0k2017
$129m2018
$26.7m2019
$336m2020
$48.7m2021
$108m2022
$331m2023
$0k2024
$0k2025
2016: $0k; 2017: $0k; 2018: $129m; 2019: $26.7m; 2020: $336m; 2021: $48.7m; 2022: $108m; 2023: $331m; 2024: $0k; 2025: $0k
Denali Therapeutics revenue and net income by year
YearRevenueNet income
2025$0k−$513m
2024$0k−$423m
2023$331m−$145m
2022$108m−$326m
2021$48.7m−$291m
2020$336m$71.1m
2019$26.7m−$198m
2018$129m−$36.2m
2017$0k−$88.2m
2016$0k−$86.7m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

Sold out last quarter